Introduction: The role of testosterone in health and quality of life has become increasingly visible and overtly marketed to the public. Some evidence suggests that testosterone levels in men may be low because of a variety of reasons, including stress and environmental exposures.
Objective: This study examines trends in testosterone prescriptions dispensed by military treatment facilities (MTFs).
Methods: We examined data from the Department of Defense Pharmacy Data Transaction Service to determine the nature of androgen prescriptions dispensed through MTFs from 2007 through 2011.
Results: The number of androgen prescriptions increased more than two-fold across the military from 19,494 in 2007 to 45,270 in 2011. Most prescriptions (99%) were for men. Androgen prescription rates rose 23% per year from 2007 through 2011 (p < 0.001, CI 23-24%). The prescription rate for 35- to 44-year-olds increased more than any other age group, with annual increases averaging 33% (p < 0.001, CI 32-34%).
Conclusion: The number of androgen prescriptions within MTFs rose significantly from 2007 through 2011. This is similar to rises in androgen prescriptions seen in civilian medical systems. Clinical indications for the sharp increase in testosterone prescriptions are unknown, and the indications for clinically appropriate testosterone replacement need further clarification.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7205/MILMED-D-14-00496 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hormonal Contraception and Bone Metabolism: Emerging Evidence from a Systematic Review and Meta-Analysis of Studies on Post-Pubertal and Reproductive-Age Women.
Pharmaceuticals (Basel)
January 2025
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Infant Health, University of Genoa, 16132 Genova, Italy.
Background/objectives: This study aims to assess the effects of combined hormonal contraceptives (CHCs) on bone metabolism markers. It primarily measures osteocalcin and additionally examines other bone health markers, seeking to determine their responses to estrogen-progestogen treatments.
Methods: This study involved a comprehensive evaluation of the pertinent literature and a meta-analysis explicitly conducted on data describing women of reproductive age.
Community pharmacy's role in dispensing androgens and supporting harm reduction amid current policy dilemmas.
Subst Abuse Treat Prev Policy
January 2025
Griffith Centre for Mental Health, Griffith University, Brisbane, QLD, Australia.
Background: Legitimate androgen use, such as testosterone replacement therapy, requires a legal prescription. Off-label use for reasons like wellness and aesthetics continues to grow. Recent regulatory changes in Australia aim to curb non-prescribed androgen use, potentially intensifying stigma, however seeking prescriptions through legal channels persists.
View Article and Find Full Text PDFInitial treatment and resource utilization among patients with metastatic-castration sensitive prostate cancer in Japan: a retrospective real-world study.
Jpn J Clin Oncol
December 2024
Market Access & Public Affairs, Bayer Yakuhin, Ltd., Osaka, Japan.
Objectives: The introduction of novel drugs for metastatic castration-sensitive prostate cancer has expanded treatment options for patients. Associated changes in healthcare resource utilization may have occurred in tandem, but nationwide information is limited. This study aimed to describe initial treatment patterns and healthcare resource utilization (including costs) for patients with metastatic castration-sensitive prostate cancer in routine clinical practice in Japan.
View Article and Find Full Text PDFTrends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer.
Cancer Med
December 2024
Department of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Objective: We aimed to examine trends in novel antiandrogen receptor signal inhibitor (ARSI) usage and medical costs by collecting real-world big data included in The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data, covering most of the clinical practices throughout Japan.
Methods: Usage data for outpatient prescriptions from 2016 to 2021 were extracted from the NDB Open Data. Among the 459,610 million tablets/capsules prescribed, prostate cancer-specific agents (bicalutamide, estramustine phosphate, flutamide, abiraterone, enzalutamide, apalutamide, and darolutamide) were selected to investigate the trends of usage and medical costs.
Medication Prescription Policy for US Veterans With Metastatic Castration-Resistant Prostate Cancer: Causal Machine Learning Approach.
JMIR Med Inform
November 2024
School of Medicine, Saint Louis University, St. Louis, MO, United States.
Article Synopsis
- - Prostate cancer is the second leading cause of death in American men, but early detection and treatment can be curative; advanced stages like mCRPC pose significant mortality risks.
- - This study examined how different medications (abiraterone and enzalutamide) affect the survival duration of patients with mCRPC, using machine learning to analyze patient demographics and health data.
- - Findings revealed that veterans treated with enzalutamide had an average increase of approximately 60 days in survival compared to those treated with abiraterone, highlighting the potential for tailored treatment strategies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!